SEC Form 13F
| Report period | 2026-06-30 |
|---|---|
| Publicly available | 2026-08-15 |
| Reported value | $263,223,000 |
| Positions | 18 |
| Issuer | Ticker | Class | Reported value | Reported amount |
|---|---|---|---|---|
| ENANTA PHARMACEUTICALS INC | ENTA | COM | $41,788,000 | 2,866,138 |
| JAZZ PHARMACEUTICALS PLC | JAZZ | COM | $40,439,000 | 167,816 |
| UNITED THERAPEUTICS CORP | UTHR | COM | $37,539,000 | 69,282 |
| BIOMARIN PHARMACEUTICAL INC | BMRN | COM | $30,028,000 | 524,786 |
| EXELIXIS INC | EXEL | COM | $20,169,000 | 370,693 |
| ABBOTT LABORATORIES | ABT | COM | $18,148,000 | 200,000 |
| SANOFI-ADR | SNY | COM | $13,820,000 | 323,946 |
| SUPERNUS PHARMACEUTICALS INC | SUPN | COM | $13,054,000 | 280,681 |
| ULTRAGENYX PHARMACEUTICAL IN | RARE | COM | $13,051,000 | 390,879 |
| VANDA PHARMACEUTICALS INC | VNDA | COM | $7,224,000 | 1,180,388 |
Public filing evidence only. NexusTrade's simulated follower strategies are hypothetical, modeled results — not live trading returns and not investment advice.